93 related articles for article (PubMed ID: 7530827)
1. Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site.
Herbst R; Munemitsu S; Ullrich A
Oncogene; 1995 Jan; 10(2):369-79. PubMed ID: 7530827
[TBL] [Abstract][Full Text] [Related]
2. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein.
Majumder S; Ray P; Besmer P
Oncogene Res; 1990; 5(4):329-35. PubMed ID: 1697669
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analyses of the kit receptor for the steel factor.
Blechman JM; Lev S; Givol D; Yarden Y
Stem Cells; 1993 Jul; 11 Suppl 2():12-21. PubMed ID: 7691317
[TBL] [Abstract][Full Text] [Related]
5. Transforming mechanism of the feline sarcoma virus encoded v-fms oncogene product.
Tamura T; Hadwiger-Fangmeier A; Simon E; Smola U; Geschwill H; Schütz B; Trouliaris S; Boscheck B; Niemann H; Bauer H
Behring Inst Mitt; 1991 Jul; (89):93-9. PubMed ID: 1834054
[TBL] [Abstract][Full Text] [Related]
6. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
7. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor).
Roussel MF; Dull TJ; Rettenmier CW; Ralph P; Ullrich A; Sherr CJ
Nature; 1987 Feb 5-11; 325(6104):549-52. PubMed ID: 3027579
[TBL] [Abstract][Full Text] [Related]
8. Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes.
Shibuya M; Matsushime H; Yamazaki H; Wang LH; Fukui Y; Ueyama Y; Tamaoki N
Princess Takamatsu Symp; 1986; 17():195-202. PubMed ID: 3455414
[TBL] [Abstract][Full Text] [Related]
9. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
[TBL] [Abstract][Full Text] [Related]
10. A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn.
Ellis C; Kasmi F; Ganju P; Walls E; Panayotou G; Reith AD
Oncogene; 1996 Apr; 12(8):1727-36. PubMed ID: 8622893
[TBL] [Abstract][Full Text] [Related]
11. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family.
Besmer P; Murphy JE; George PC; Qiu FH; Bergold PJ; Lederman L; Snyder HW; Brodeur D; Zuckerman EE; Hardy WD
Nature; 1986 Apr 3-9; 320(6061):415-21. PubMed ID: 3007997
[TBL] [Abstract][Full Text] [Related]
12. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
13. Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III.
André C; Martin E; Cornu F; Hu WX; Wang XP; Galibert F
Oncogene; 1992 Apr; 7(4):685-91. PubMed ID: 1373482
[TBL] [Abstract][Full Text] [Related]
14. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Jackson PK; Paskind M; Baltimore D
Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
[TBL] [Abstract][Full Text] [Related]
15. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
16. Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.
Kubota Y; Angelotti T; Niederfellner G; Herbst R; Ullrich A
Cell Growth Differ; 1998 Mar; 9(3):247-56. PubMed ID: 9543391
[TBL] [Abstract][Full Text] [Related]
17. Catalytic activity and transformation potential of v-Src require arginine 385 in the substrate binding pocket.
Senften M; Schenker G; Sowadski JM; Ballmer-Hofer K
Oncogene; 1995 Jan; 10(1):199-203. PubMed ID: 7529917
[TBL] [Abstract][Full Text] [Related]
18. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.
Kanakura Y; Furitsu T; Tsujimura T; Butterfield JH; Ashman LK; Ikeda H; Kitayama H; Kanayama Y; Matsuzawa Y; Kitamura Y
Leukemia; 1994 Apr; 8 Suppl 1():S18-22. PubMed ID: 7512180
[TBL] [Abstract][Full Text] [Related]
19. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.
Qiu FH; Ray P; Brown K; Barker PE; Jhanwar S; Ruddle FH; Besmer P
EMBO J; 1988 Apr; 7(4):1003-11. PubMed ID: 2456920
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells.
Serve H; Hsu YC; Besmer P
J Biol Chem; 1994 Feb; 269(8):6026-30. PubMed ID: 7509796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
